Compare Equinix Inc (EQIX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Sanofi SA — how do they compare? Equinix Inc trades at $1,061.7 (market cap $101.87B), while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Equinix Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| EQIX | SNY | |
|---|---|---|
Market Cap | $101.87B | $104.30B |
Sector | Real Estate | Health |
52-Week High | $1.12K | $52.34 |
52-Week Low | $726.09 | $41.33 |
Enterprise Value | $123.00B | $124.19B |
Dividend Yield | 2% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,061.19, up 1.71% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing revenue expectations. Strong demand for AI infrastructure and record bookings support a raised long-term growth outlook. However, high valuation ratios, including a P/E of 66.44 and EV/EBITDA of 27.58, reflect premium pricing. Cash flow trends show significant capital expenditures, with net cash flow negative in 2025 and 2026.
The outlook for EQIX is cautiously optimistic, driven by AI-driven demand and strategic partnerships, but elevated debt levels and valuation multiples pose risks. Analyst consensus is strongly bullish with a $1,120 price target, though investors should monitor execution on growth targets and debt management amid competitive and macroeconomic pressures.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
